New cancer drug targets tough tumors in early trial
NCT ID NCT07260513
First seen Jan 11, 2026 · Last updated May 16, 2026 · Updated 18 times
Summary
This early-stage study tests a new drug called GH2616 in people with advanced solid tumors that have not responded to other treatments. The drug works by blocking a protein that helps cancer cells divide, which may stop tumor growth. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
-
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
Conditions
Explore the condition pages connected to this study.